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Abstract
Background: Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibitors (TKIs) like erlotinib are effective for
treating patients with EGFR mutant lung cancer; however, drug resistance inevitably emerges. Approaches to
combine immunotherapies and targeted therapies to overcome or delay drug resistance have been hindered by
limited knowledge of the effect of erlotinib on tumor-infiltrating immune cells.
Methods: Using mouse models, we studied the immunological profile of mutant EGFR-driven lung tumors before
and after erlotinib treatment.
Results: We found that erlotinib triggered the recruitment of inflammatory T cells into the lungs and increased
maturation of alveolar macrophages. Interestingly, this phenotype could be recapitulated by tumor regression mediated
by deprivation of the EGFR oncogene indicating that tumor regression alone was sufficient for these immunostimulatory
effects. We also found that further efforts to boost the function and abundance of inflammatory cells, by combining
erlotinib treatment with anti-PD-1 and/or a CD40 agonist, did not improve survival in an EGFR-driven mouse model.
Conclusions: Our findings lay the foundation for understanding the effects of TKIs on the tumor microenvironment and
highlight the importance of investigating targeted and immuno-therapy combination strategies to treat EGFR mutant
lung cancer.
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Background
EGFR mutations are found in 10–15% of lung adenocar-
cinomas in the US and are enriched in tumors from
never or former smokers [1]. Lung adenocarcinoma-
associated mutations in exons encoding the tyrosine kin-
ase domain of this receptor most commonly include either
deletion of a four amino acid motif (LREA) in Exon 19 of
EGFR or a point mutation in Exon 21, which substitutes
Arginine for Leucine at position 858 (L858R) [2]. These
mutations confer sensitivity to EGFR tyrosine kinase in-
hibitors (TKIs) such as erlotinib, gefitinib and afatinib,
current standard of care therapies for the treatment of this
subset of lung cancer. However, drug resistance inevitably
develops on average after 12months of treatment [3, 4].
In more than 50% of cases, acquired resistance to erlotinib
is driven by a second site mutation in EGFR, T790M [3,
5], which alters the affinity of the receptor for ATP and as
a consequence to the drugs [6]. Novel 3rd generation TKIs
that specifically inhibit mutant EGFR (and spare wild-type
EGFR) are now also approved to treat this disease in both
the first and second line settings to overcome and/or delay
the onset of resistance [7]. Even with these improvements,
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however, none of the therapies are curative [8]. Therefore,
demands for novel therapeutic approaches are high.
Recent advances show that targeting the immune system
is a useful approach to treating lung cancer. Mounting evi-
dence suggests that tumors stimulate the establishment of
an immunosuppressive microenvironment to evade the im-
mune system by facilitating tumor-infiltrating T cells to dis-
play an exhausted phenotype [9] such that they are unable
to proliferate and produce pro-inflammatory cytokines [10,
11]. Agents that target inhibitory molecules (e.g. PD-1,
CTLA4) on T cells and/or their cognate ligands (e.g. PD-
L1) on tumor and immune infiltrating cells have shown
promising results in treating lung cancers and are now
FDA-approved. However, overall there appears to be a
lower response rate to PD-1 axis inhibitors associated with
EGFR mutations. In a retrospective evaluation of patients
treated with PD-1 or PD-L1 inhibitors, it was found that
objective responses in patients with EGFR-mutant tumors
was 3.6% compared to 23.3% in those with EGFR wild-type
tumors [12]. In spite of this, there are clear indications that
a subset of patients with EGFR mutant lung cancer benefit
from these therapies [13–15]. Moreover, preclinical models
demonstrate that the immune system plays an important
role in modulating the growth of EGFR mutant tumors
[16]. In one study evaluating the combination of erlotinib
plus nivolumab, durable tumor regression in both treat-
ment (TKI or chemotherapy) naïve and TKI-treated pa-
tients was reported [17] and there are several additional
trials evaluating the efficacy of combining PD-1/PD-L1 in-
hibitors with EGFR TKIs [13]. However, toxicities have
raised concerns that treating patients with EGFR TKIs and
immune checkpoint inhibitors concurrently may not be the
optimal approach to use these agents in combination.
Given these findings, studies are necessary to understand
the effects of EGFR TKIs on the tumor microenvironment
and the immunological consequences of combining im-
mune checkpoint inhibitors with EGFR TKIs.
Several studies have examined the effect of kinase in-
hibitors on the tumor immune microenvironment. The
BRAF inhibitor vemurafenib, for instance, has been re-
ported to increase intratumoral CD8+ T cell infiltrates
[18], increase tumor associated antigens and improve ef-
fector function of cytotoxic T lymphocytes [19]. How-
ever, a subset of tumors resistant to vemurafenib exhibit
features of T-cell exhaustion and reduced antigen pres-
entation suggesting that these may be resistant to check-
point inhibitors [20]. Similarly, in lung cancer cell lines,
two studies have revealed that TKI treatment leads to
down-regulation of tumor PD-L1 expression [21, 22].
Moreover, it has also been shown that erlotinib can im-
pair T cell-mediated immune responses via suppression
of signaling pathways downstream of EGFR critical for
cell survival and proliferation [23]. Further supporting
that erlotinib could have immunosuppressive effects on
the immune system, erlotinib has been posited to down-
regulate TNF-α mediated inflammation characteristic of
psoriasis [24]. In addition, a study in mouse models of
EGFR mutant lung cancer reported increased leukocyte
infiltration and enhanced antigen-presenting capabilities
after 24 h of erlotinib treatment [25]. While these studies
point to modulation of the immune system by TKIs like
erlotinib several unanswered questions remain: 1) in
addition to the abundance, how is the functionality of
the immune cells affected by erlotinib, and specifically of
lung-resident immune cells that have not been examined
in prior studies? 2) does the immune microenvironment
return to normal after tumor regression or are there lin-
gering consequences of the presence of the tumor? 3)
are the effects of erlotinib treatment in vivo on the im-
mune microenvironment mediated by erlotinib or are
they due to the process of tumor regression? and 4) what
are the more long-term effects of erlotinib on the im-
mune microenvironment beyond the effects observed
acutely after treatment? To address these issues, we uti-
lized a previously developed immunocompetent mouse
model of EGFR mutant lung cancer [26] and tested the




CCSP-rtTA; TetO-EGFRL858R mice were previously de-
scribed [26]. Mice were fed chow containing doxycycline
(625 ppm) obtained from Harlan-Tekland. The animals
were housed in a pathogen-free facility and animal stud-
ies were performed in accordance with and with the ap-
proval of the Yale University Institutional Animal Care
and Use Committee (IACUC protocol numbers: 2016–
11364, 2016-10806 and assurance number: D16–00416).
In vivo treatment with Erlotinib
Erlotinib was purchased and purified at the organic syn-
thesis core facility at Memorial Sloan Kettering Cancer
Center (MSKCC), dissolved in 0.5% methylcellulose and
administered intraperitoneally at 25 mg/kg, 5 days a
week. Mice were euthanized by CO2 asphyxiation.
Magnetic resonance imaging
Magnetic resonance images of isofluroane-anesthetized
mice were collected using a mini-4 T horizontal-bore
spectrometer (Bruker AVANCE). Throughout data col-
lection, each animal was anesthetized on a steady flow of
isofluroane and oxygen (2–2.5% v/v) and core-body
temperature was maintained at 37 ± 1 °C. Imaging pa-
rameters were optimized to effectively discriminate be-
tween healthy lung and areas with tumor. Tumor
burden in each animal was quantified by calculating the
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volume of visible lung opacities in every image sequence
using the BioImage Suite software [27].
Tumor digestion
Lungs from normal, untreated, tumor-bearing or treated
mice were mechanically digested and incubated in HBSS
with 0.5 mg/ml collagenase IV and 1μg/ml DNase 1 at
37 degrees for 1 h after which the solution was filtered
using a 70 μm cell strainer. The resulting single cell sus-
pension was incubated in ACK lysis buffer for 5 min to
lyse red blood cells.
Flow cytometry and cell sorting
Single cell suspensions of lung tumors or splenocytes
were resuspended in FACS buffer (PBS + 1%FBS). Cells
were then incubated with anti-Fc receptor antibody
(clone 2.4G2) on ice for 15 min followed immediately by
staining with respective surface antibodies for 30 min.
For intracellular cytokines, T cells were stimulated with
PMA/ionomycin (Sigma Aldrich) and Brefeldin A for 5 h
at 37 degrees. The cells were stained first with surface
antibodies then fixed in Cytofix/Cytoperm buffer (BD
Biosciences) followed by staining with antibodies to de-
tect proteins present in intracellular compartments.
FoxP3 staining was done in a similar manner. Samples
were acquired on an LSRII flow cytometer and analyzed
with Flowjo. Cells were sorted on the BD FACS Aria at
the Yale Cell Sorter Core facility. Cells were sorted based
on the expression of the following markers: CD4 T cells:
CD45+/CD3+/CD4+, CD8 T cells: CD45+/CD3+/CD8+,
Alveolar macrophages: CD45+/ CD11c+/SiglecF+,
Tumor epithelial cells: CD45−/CD11c-Epcam+.
In vivo labeling of immune cells
Mice were retro-orbitally injected with 3 μg of biotin-
conjugated CD45 (clone 30-F11) for 5 min, immediately
after which animals were sacrificed. Lung tissue was col-
lected, processed and stained as described above.
T cell proliferation assay
Splenocytes and single cell suspensions were collected
from spleen or lungs of tumor bearing mice. T cells were
enriched using a purified antibody cocktail consisting of
IA/I-E, B220 and F4/80. Purified cells were loaded with
5 μM CFSE at room temperature for 15 min in the dark.
T cells mixed with anti-CD28 were seeded on CD3
coated plates followed by treatment with 10 μM Erloti-
nib or DMSO for 5 days. Proliferation was determined
by CFSE dilution using flow cytometry.
Histology, immunofluorescence and cell quantification
Lung tissue from normal, tumor bearing untreated and
treated animals was collected after sacrifice, fixed over-
night in 4% paraformaldehyde and rehydrated in 70%
ethanol until submission for paraffin embedding and
sectioning at the Yale Pathology Tissue Services. Sec-
tions were stained with hematoxylin and eosin, CD3
(Spring Biosciences; 1:150), EGFRL858R (Cell Signaling; 1:
400), FoxP3 APC-conjugated (eBioscience; 1:50), Ki-67
(BioLegend; 1:50) and Cytokeratin 7 (Abcam; 1:300)
antibodies. Positive cells in a 40X field of view were
manually counted using a plugin for ImageJ called Cell
Counter. At least three representative tissue locations
were used to quantify and values were averaged for each
mouse.
Bio-Plex Cytokine assay
Healthy lungs or tumors were crushed and homogenized
in cold PBS with 1X protease inhibitor cocktail and 1%
Triton X-100 (Thermo Scientific). Equal amounts of
total protein were analyzed in triplicates using the Bio-
Rad Mouse 23-plex cytokine assay (Bio-rad, CA, USA)
according to the manufacturer’s protocol.
RNA extraction, purification and quantitative real-time RT-
PCR
For RNA extraction and purification, the Arcturus PicoPure
RNA isolation kit was used according to manufacturer’s in-
struction and cDNA was synthesized using the SuperScript
II Reverse Transcriptase from Invitrogen. Quantitative real-
time PCR was performed using the Taqman assay (Invitro-
gen). Ct values were recorded and relative gene expression
was determined using the ΔΔCt method.
RNA sequencing and gene expression data
RNA sequencing was performed using the illumina HiSeq
2000 platform through the Yale Stem Cell Center Genom-
ics Core facility. R1 reads from each paired-end reads were
aligned to the mouse genome (version mm10) using bow-
tie2 [28] in local mode, followed by annotation of counts
to each gene by gencode (version M10) [29]. Differential
expression in each cell type between experimental condi-
tions was performed with the DESeq2 [30] R package.
Ingenuity pathway analysis
Enrichment analyses of canonical pathways were per-
formed with Ingenuity Pathway Analysis (IPA, Ingenuity
Systems). Genes with an adjusted P value lower than
0.05 were included and Ingenuity Knowledge Base
(Genes Only) was used as reference set for the analyses.
Statistical analysis
Statistical analysis was performed using GraphPad Prism
7.0 software and p-values, where indicated, were deter-
mined using the parametric, student’s t-test.
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In vivo treatment with erlotinib, agonistic anti-CD40
antibody and anti-PD-1 antibody
Tumor bearing EGFRL858R mice were treated with erlotinib
alone or in combination with an agonistic anti-CD40 anti-
body and/or anti-PD-1 antibody. Erlotinib (obtained from
the Organic Synthesis Core Facility at Memorial Sloan Ket-
tering Cancer Center) was suspended in 0.5% (w/v) methyl-
cellulose. The agonistic anti-CD40 antibody and anti-PD-1
antibody (both from BioXcell) were diluted in PBS. Erlotinib
was administered intraperitoneally at 25mg/kg per mouse, 5
days a week while the agonistic anti-CD40 antibody and
anti-PD-1 antibody were administered intraperitoneally at
250 μg/mouse, every 3 days. Tumor volume was assessed by
MRI before, during and after treatment duration and at the
end of study, mice were euthanized by CO2 asphyxiation.
Results
Increased inflammatory T cells following erlotinib
treatment in EGFR mutant lung cancer mouse models
To evaluate the changes that occur in the immune
microenvironment upon TKI treatment, CCSP-rtTA;
TetO-EGFRL858R bitransgenic mice on a doxycycline diet
were treated with erlotinib, an EGFR TKI, for a period
of 2 weeks (Fig. 1a). In six tumor bearing mice after 2
weeks of erlotinib treatment, the disease is mostly
undetectable by Magnetic Resonance Imaging (MRI)
(Additional file 1: Figure S1A) and largely resolved histo-
pathologically (Additional file 1: Figure S1B). At the end
of the treatment, lung and spleen single cell suspen-
sions were prepared and analyzed by flow cytometry.
We compared the immune profiles of normal healthy
lungs from four mice and lungs from six tumor-
bearing untreated and six erlotinib-treated mice. To
ensure that the effects observed were not due to the
presence of doxycycline in the mouse diet, all of the
mice, including controls were maintained on doxycyc-
line for the same amount of time. We found a con-
sistent reduction in the fraction of CD45+ immune
cells and the absolute number of CD4+ and CD8+ T
cells per gram of lung tissue in untreated tumor-
bearing lungs that was reversed upon TKI treatment
(Fig. 1b and Additional file 1: Figure S1C&D).
To determine whether there were any differences in
the T cells in tumor-bearing lungs indicative of an im-
munosuppressive microenvironment, we quantified
regulatory T cells present in the different conditions. We
observed a significant increase in Foxp3+ regulatory T
cells (Tregs) in the lungs of tumor-bearing mice regard-
less of erlotinib treatment (Fig. 1c and Additional file 1:
Figure S1E) suggesting that these immunosuppressive
cells, which also may play a role in tissue repair, are
retained even following erlotinib-mediated tumor regres-
sion. Despite the lack of a major shift in the proportion
of Tregs in the erlotinib-treated lungs, the Treg/CD8
+ T
cell ratio decreased with erlotinib treatment, likely due
to the increase in CD8+ T cells and indicative of a shift
A B
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Fig. 1 The immunosuppressive microenvironment in murine EGFRL858R –induced lung adenocarcinomas is partially reversed by erlotinib. (a)
Experimental outline of tumor induction and erlotinib treatment. CCSP-rtTA; TetO-EGFRL858R mice and littermate controls on a doxycycline diet
(green arrow) for 6–7 weeks were treated with erlotinib or left untreated for 2 weeks. Infiltrating immune cells were analyzed by flow cytometry.
Quantification of (b) CD4 and CD8 T cells (c) FoxP3 positive CD4 T cells (d) Treg/ CD8+ T cell ratio and (e) PD-1 positive FoxP3- and FoxP3+ CD4
and CD8 T cells in the lungs (and spleens) of normal lung (NL) and tumor bearing CCSP-rtTA; TetO-EGFRL858R mice in the absence (−) and
presence (+) of erlotinib for 2 weeks. Data are obtained from three independent experiments, (n = 4–6 mice per group). Data are shown as
mean ± SD and * is P < 0.05 in a student’s t-test
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towards a more immunostimulatory microenvironment
(Fig. 1d). Interestingly, these Tregs retained a high level
of PD-1 expression that was unchanged with erlotinib
treatment (Fig. 1e and Additional file 1: Figure S1F). To
confirm these findings using an orthogonal approach, we
used immunofluorescence to detect the tumor cell
marker, cytokeratin, a pan T cell marker CD3, and
the Treg marker, Foxp3. We observed that erlotinib
treatment induced infiltration of T cells into the lungs
compared to untreated tumor-bearing lungs
(Additional file 1: Figure S1G). Our quantification of
Foxp3+ cells from these sections also revealed that
there was no significant difference in their abundance
between untreated and erlotinib-treated lungs
(Additional file 1: Fig. S1H). In vitro T cell stimula-
tion assays demonstrated that both CD4+ and CD8+
T cells showed increased production of the cytokines
IFN-γ, TNF-α and IL-2 after erlotinib treatment
indicative of an activated phenotype (Fig. 2a&b and
Additional file 1: Figure S2A). These results suggest
the presence of an immunosuppressive microenviron-
ment in the lungs of mice with EGFRL858R tumors,
which is consistent with findings from a mouse model
of EGFREx19del mutant lung cancer [16]. Erlotinib
treatment leads to an increase in the numbers of lym-
phocytes, their higher cytokine production and a lim-
ited reduction in the proportion of Tregs.
To further study the properties of tumor-infiltrating T
cells after erlotinib treatment, we used an in vivo label-
ing approach to distinguish circulating and parenchymal
lung T cells from tumor-bearing mice left untreated or
treated with erlotinib for 2 weeks (n = 3 mice per group)
[31]. CD4+ and CD8+ T cells in the lungs were further
classified as naïve or effector based on their expression
of molecules involved in lymphocyte migration (e.g.
CD62L) necessary for T cell entry into lymph nodes
through high endothelial venules [32] and molecules in-
volved in lymphocyte adhesion (e.g. CD44) required to
enter sites of inflamed peripheral tissues [33], where
interaction with target antigens can occur. Naïve CD4+
and CD8+ T cells, defined as CD62Lhigh CD44low, were
unchanged after erlotinib treatment (Fig. 2c). Con-
versely, percentages of CD62Llow CD44high effector




Fig. 2 Increased production and presence of immunostimulatory cytokines following erlotinib treatment. Quantification of the levels of indicated
effector cytokines from (a) CD4 T cells and (b) CD8 T cells after PMA/ionomycin stimulation and intracellular cytokine staining of cells in the lungs
of tumor bearing CCSP-rtTA; TetO-EGFRL858R mice in the absence (−) and presence (+) of erlotinib for 2 weeks. Quantification of naïve and effector
(c) CD4 and (d) CD8 T cells in lungs of CCSP-rtTA; TetO-EGFRL858R tumor bearing mice untreated or treated with erlotinib for 2 weeks. Data are
from three independent experiments, (n = 3 mice per group) (e) Quantification of chemokines and cytokines in lungs of tumor bearing CCSP-rtTA;
TetO-EGFRL858R mice in the absence (−) and presence (+) of erlotinib for 2 weeks. Proteins (from a panel of 23) with significantly different levels
between untreated and erlotinib-treated lungs are shown. Data are shown as mean ± SD and * is P < 0.05 in a student’s t-test
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treatment (Fig. 2d), suggesting that erlotinib treatment
leads to increased effector T cells in the tumor micro-
environment. There was no significant difference in the
expression of Granzyme B on CD4+ or CD8+ T cells
from tumor bearing lungs before and after erlotinib
treatment (Additional file 1: Figure S2B). Moreover,
compared to a splenocyte control (Additional file 1: Fig-
ure S2C), T cells in the lungs expressed very low Gran-
zyme B (GzmB) after in vitro stimulation. We
investigated the expression of CD107a, a marker of T
cell degranulation following stimulation, and observed
undetectable expression. This suggests that in spite of
enhanced cytokine secretion after erlotinib, the T cells in
the tumor microenvironment do not degranulate. In
order to further characterize lung CD4+ and CD8+ T
lymphocytes, we isolated lung-resident CD4+ and CD8+
T cells and performed RNA sequencing to query their
gene expression profiles. As predicted, we detected
abundant expression of T cell lineage markers Cd3e,
Cd4, Cd8a and Cd8b in the relevant cell populations
that was unchanged by erlotinib treatment (Additional
file 1: Figure S2D&E). In addition, we found that T cells
from untreated tumors and erlotinib treated tumors
have similar levels of expression of the T-cell co-
stimulatory molecules Cd28, Cd27 and Icos (Additional
file 1: Figure S2D&E). Ingenuity Pathway Analysis (IPA)
revealed leukocyte extravasation signaling and agranulo-
cyte adhesion and diapedesis (extravasation) amongst
the top ten pathways that changed significantly after er-
lotinib treatment suggesting that erlotinib treatment
modulates lymphocyte properties related to movement
and migration (Supplementary Table 1).
Next, to gain insight into the cytokine milieu present
in EGFR mutant tumors and how this changes with erlo-
tinib treatment, we used a multiplex immunoassay to
measure the protein level of 23 cytokines from whole
lung lysates of untreated and treated tumors. We found
that the T cell chemoattractants CCL2 and CCL5 in-
creased after erlotinib treatment, as did the levels of sev-
eral pro-inflammatory cytokines (e.g. IFN-γ, IL-12p40)
(Fig. 2e). Concomitant decreases in the cytokine CCL3
and chemokine CXCL1 were found. Overall, these data
suggest that erlotinib leads to changes in the lung tumor
microenvironment that are conducive to the recruitment
and survival of T cells.
Tumor regression mediated by erlotinib indirectly leads
to the changes in the immune microenvironment
We further questioned whether the effect of erlotinib on
the tumor microenvironment was a direct consequence
of the TKI or an indirect result of drug-induced tumor
regression. To address this question, we leveraged the
inducible nature of our model system and removed
doxycycline from the diet of six tumor-bearing
EGFRL858R mice for 2 weeks. Doxycycline withdrawal
turns off the transgene initiating rapid tumor cell death
similar to that observed with erlotinib (n = 6 mice) [26],
(Fig. 3a and Additional file 1: Figs. S3A and B). As is the
case with erlotinib, we saw an increase in the percentage
of CD4+ and CD8+ T cells in the lungs of these models
(Fig. 3b, Additional file 1: Figure S3C and D). Dox with-
drawal had a more profound effect on Tregs which de-
creased significantly following oncogene de-induction
(along with a corresponding decrease in the Treg/CD8
ratio) compared to what was observed with erlotinib
treatment (Fig. 3c and d). To further explore whether
tumor regression, and not erlotinib directly, was causing
the observed changes in the immune microenvironment,
we studied mice with EGFR mutant lung cancer induced
by expression of the EGFRL858R + T790M mutant that is
unresponsive to erlotinib treatment (Additional file 1:
Figs. S3A and B) [34]. Following erlotinib treatment of
six L + T tumor-bearing mice we did not observe
changes in the immune microenvironment (Fig. 3b,
c&d). We also treated mono-transgenic (either TetO-
EGFRL858R+;CCSP-rtTA- or TetO-EGFRL858R-;CCSP-
rtTA+) healthy littermates with erlotinib for 2 weeks as
an alternative approach to query whether the inhibitor
exerts non-specific effects on immune cells and ob-
served no differences in the immune microenvironment
between erlotinib treated or untreated lungs (n = 4 mice
per group) (Additional file 1: Fig. S3E and F). These re-
sults lead us to conclude that the changes in the im-
mune microenvironment are not a result of a direct
effect of erlotinib on immune cells but rather a conse-
quence of the process of tumor regression itself.
To further study whether erlotinib directly affects
tumor-infiltrating T cells we used in vivo labeling to dis-
tinguish circulating (i.e., cells in the vasculature) and
parenchymal lung T cells followed by flow cytometry
analysis. Notably, erlotinib treatment led to an increase
in the absolute number of T cells present in the lung
epithelium compared to untreated tumor-bearing lungs
(n = 6 mice per group) (Fig. 4a). This translated into a 4-
fold increase in CD4+ T cells and 2-fold increase in
CD8+ T cells (Fig. 4b). This difference was not as prom-
inent in the circulating T cells collected from the mouse
lungs (Additional file 1: Figure S4A & B). Interestingly,
the lung CD4+ and CD8+ T cells showed decreased
Ki-67 positivity upon erlotinib treatment suggesting
that the increased number of these cells was not due
to increased proliferation following erlotinib treatment
(Fig. 4c). Co-immunofluorescent staining of lung sec-
tions with antibodies against CD3 and Ki-67 showed
a similar trend (Fig. 4d and e). Analogous findings
were observed in samples from mice following doxy-
cycline withdrawal (n = 4) supporting the possibility
that the decrease in T cell proliferation is an indirect
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effect of the tumor regression rather than a direct
effect of erlotinib on the T cells (Additional file 1:
Figure S4C).
To further confirm that erlotinib did not act
directly on T cells, we evaluated its effect on T cell
proliferation by performing CFSE staining (Additional
file 1: Figure S5A and B) of 10 μM erlotinib and
DMSO-treated T cells isolated from spleens and lungs
of tumor-bearing mice. We found that erlotinib, even
at this high concentration, did not alter T cell
proliferation in vitro (Fig. 5a, b and Additional file 1:
Figure S5C). We also tested the effects of this TKI on
T cells after LCMV infection in vivo (Fig. 5c) and
found no effect on the abundance of CD44+ activated
A B
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Fig. 3 Changes in T cells in the immune microenvironment are due to tumor regression. (a) Experimental outline of tumor induction and
erlotinib treatment. CCSP-rtTA; TetO-EGFRL858R or CCSP-rtTA; TetO-EGFRL858R + T790M mice and littermate controls on a doxycycline diet (green arrow)
were treated with erlotinib or left untreated for 2 weeks or taken off doxycycline diet. Infiltrating immune cells were analyzed by flow cytometry.
Quantification of (b) CD4 and CD8 T cells, (c) FoxP3 positive CD4 T cells and (d) the Treg/ CD8 ratio in lungs of tumor bearing CCSP-rtTA; TetO-
EGFRL858R or CCSP-rtTA; TetO-EGFRL858R + T790M mice in the absence (−) and presence (+) of erlotinib for 2 weeks or after doxycycline withdrawal.
Data are from three independent experiments, (n = 4–6 mice per group). Data are shown as mean ± SD and * is P < 0.05 in a student’s t-test
A B C
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Fig. 4 Erlotinib-mediated tumor regression increases lung T cells. (a) Absolute number and (b) Fold change in number of parenchyma lung CD4
and CD8 T cells of tumor bearing CCSP-rtTA; TetO-EGFRL858R mice in the absence (−) and presence (+) of erlotinib for 2 weeks. Quantification of (C)
Ki-67+ CD4 and CD8 T cells of tumor bearing CCSP-rtTA; TetO-EGFRL858R mice in the absence (−) and presence (+) of erlotinib for 2 weeks. (d)
Immunofluorescent (IF) stain and (e) quantification of CD3 T cells (red) and Ki-67 positive cells (Cyan) in lungs of tumor bearing CCSP-rtTA; TetO-
EGFRL858R mice in the absence (−) and presence (+) of erlotinib for 2 weeks. Nuclei were counterstained with Dapi (blue). Data are obtained from
three independent experiments, (n = 4–6 mice per group). Data are shown as mean ± SD and * is P < 0.05 in a student’s t-test
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CD4+ or CD8+ T cells with erlotinib treatment (Fig. 5d&e).
In addition, we did not observe a significant difference in
Ki67+ CD4+ or CD8+ T cells between erlotinib and vehicle
treated mice (n= 3 mice per group) suggesting that erlotinib
does not affect proliferation of these cells directly (Fig. 5f).
Erlotinib treatment leads to increased maturation of
myeloid cells
First, we investigated the proportions of myeloid cell
populations following erlotinib treatment. Specifically,
we measured the percentage of alveolar and interstitial
macrophages, neutrophils and dendritic cells (Fig. 6a).
As observed by others [35], there was a prominent ex-
pansion of alveolar macrophages (AM) in tumor-bearing
mouse lungs and this cell population was significantly
decreased after erlotinib treatment (Fig. 6a) likely due to
decreased proliferation of those cells as shown by a
lower percentage of Ki-67+ positivity in that population
after TKI treatment (Additional file 1: Figure S6A). In
direct opposition to the pattern observed with AMs,
interstitial macrophages and neutrophils were decreased
in tumor-bearing lungs compared to controls and in-
creased after erlotinib treatment, (n = 4–6 mice per
group) (Fig. 6a). Dendritic cells were notably absent in
tumor-bearing untreated lungs compared to their
healthy lungs counterpart. We did observe a significant
increase in CD103+ dendritic cells after erlotinib treat-
ment (Fig. 6a).
Pulmonary AMs serve diverse roles in defense against
pathogens in the respiratory tract. In addition to their
well-established phagocytic roles and microbicidal func-
tions [36], they also initiate pro-inflammatory responses
through secretion of cytokines, which can stimulate T
helper type 1 (TH1) responses or anti-inflammatory re-
sponses through secretion of IL-10 [37]. Finally, AMs
have been described as poor antigen presenting cells,
due to low expression of the co-stimulatory molecules
CD80 and CD86 [38]. We observed an increase in the
mean fluorescence intensity of CD86 on AMs suggesting
a mature antigen presenting phenotype (Fig. 6b). Further
supporting a switch in the macrophages to a pro-




Fig. 5 Erlotinib does not diminish T cell proliferation in vitro or in vivo. Quantification of erlotinib-treated (a) CD8 and (b) CD4 T cells isolated
using magnetic beads from lungs and spleens of tumor bearing four CCSP-rtTA; TetO-EGFRL858R + T790M mice and labeled with CFSE. The proportion
of dividing cells was assessed 120 h after 10 μm erlotinib or DMSO treatment based on CFSE dilution. (c) Experimental layout of control, non-
tumor bearing CCSP-rtTA; TetO-EGFRL858R mice infected with LCMV for 8 days with intervening daily administration of erlotinib or vehicle for 5 days,
(n = 3 mice per group). Splenic T cells were collected and analyzed by flow cytometry. (d) Representative FACS plot showing the percentage of
CD44+ CD4+ or CD44+ CD8+ T cells and quantification of (e) CD44+ CD4+ or CD44+ CD8+ T cells. (f) Ki-67+ CD4+ or Ki-67+ CD8+ T cells from
vehicle or erlotinib treated LCMV infected mice. Data are shown as mean ± SD and * is P < 0.05 in a student’s t-test
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in AMs isolated from erlotinib-treated lungs (Fig. 6c).
High expression of Irf5 has been shown to be character-
istic of pro-inflammatory M1 macrophages, which are
potent promoters of TH1 responses [39]. The levels of
expression of M2 macrophage markers such as
Chitinase-like 3 or MRC-1 were unchanged in lung
tumors compared to healthy lungs or after erlotinib
treatment. Interestingly, gene expression of Cxcl2
increased in AMs after erlotinib treatment (Additional
file 1: Figure S6B). This could potentially explain the
increased neutrophils observed in TKI-treated lungs




Fig. 6 Erlotinib decreases alveolar macrophages and mediates a macrophage phenotypic switch indicative of an improved maturation.
Quantification of (a) myeloid cell populations, (b) mean fluorescent intensity of the co-stimulatory molecule, CD86 in alveolar macrophages (AMs),
(c) Irf5 and (d) Cd274 mRNA expression in AMs (E) PD-L1 mean fluorescent intensity on AMs in lungs of control (normal) and tumor bearing
CCSP-rtTA; TetO-EGFRL858R mice in the absence (−) and presence (+) of erlotinib for 2 weeks. (f) Quantification of myeloid cell populations in lungs
of tumor bearing CCSP-rtTA; TetO-EGFRL858R treated with erlotinib or taken off doxycycline diet for 2 weeks or CCSP-rtTA; TetO-EGFRL858R + T790M mice
in the absence (−) and presence (+) of erlotinib for 2 weeks. Data are obtained from three independent experiments, (n = 4–6 mice per group).
Data are shown as mean ± SD and * is P < 0.05 in a student’s t-test
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tumor regression treatment triggers an inflammatory re-
sponse in AMs.
Since a decrease in CD8+ T cell responses can be me-
diated by immune checkpoint ligands such as PD-
Ligand 1 (PD-L1 or B7H1), we investigated whether the
levels of this molecule were modulated by erlotinib. We
found increased Cd274 (the gene encoding Pd-l1) ex-
pression and Pd-l1 protein on AMs after erlotinib treat-
ment (Fig. 6d&e), perhaps as a consequence of an
adaptive immune response triggered by the inflamma-
tory microenvironment induced by erlotinib. Moreover,
IFN-γ secreted by activated effector T cells, described
earlier, has been shown to induce Pd-l1 in mouse models
[40]. However, we did not observe a significant differ-
ence in expression of Cd274 on Epcam+ cells from nor-
mal lungs compared to cells from tumor bearing or
erlotinib treated lungs (Additional file 1: Figure S6C).
Here, we also queried whether the effect of erlotinib on
myeloid cells in the tumor microenvironment was a dir-
ect consequence of TKI or an indirect result of drug-
induced tumor regression. We saw decreased AMs and
increased interstitial macrophages, neutrophils and den-
dritic cells after doxycycline withdrawal (Fig. 6f ). Not-
ably, in EGFRL858R + T790M mice, there was no significant
difference in any of these myeloid cell populations be-
fore and after erlotinib (n = 6 mice per group) (Fig. 6f ),
further suggesting that the changes we observed are as a
result of tumor regression. In four mono-transgenic
healthy littermates treated with erlotinib for 2 weeks, we
observed a significant reduction in the AM population
but no differences in other myeloid cell populations
(Additional file 1: Figure S6D).
Boosting T cell abundance or function does not protect
erlotinib-treated mice from tumor recurrence
Our data suggest that erlotinib largely restores the im-
mune TME to that found in non-tumor bearing lungs,
including the infiltration of cytokine-producing T cells.
We wondered whether by doing this erlotinib creates
the conditions for further therapeutic immune stimula-
tion. We postulated that boosting the immune response
to the tumors by targeting key molecules present on im-
mune cells in the TME could potentially stimulate T-cell
responses to the tumor cells and protect mice from
tumor recurrence. To investigate this possibility, we
tested the effects of therapeutic approaches to enhance
T cell activity either by blocking the PD-1/PD-L1 axis
using an anti-PD-1 antibody and/or using an agonistic
CD40 antibody on the EGFRL858R-induced tumors alone
or in combination with erlotinib. Agonistic CD40 anti-
bodies have been shown to activate antigen-presenting
cells, leading to a stimulation of T cell-specific antitumor
responses [41] and in our models, we observed an in-
crease in CD8+ T cells compared to untreated or
erlotinib treated lungs (Additional file 1: Figure S7A)
with the CD40 agonist, (n = 4–6 mice per group). Those
CD8 T cells expressed higher Ki-67 and Eomesodermin
(Eomes) (Additional file 1: Figure S7B&C) indicative of
increased proliferation and activation of the transcrip-
tional program necessary for the differentiation of ef-
fector CD8+ T cells [42]. Two-week treatment revealed
that there was no difference in tumor burden between
untreated tumors, anti-PD-1 and/or CD40 agonist-
treated tumors (Additional file 1: Figure S7D). Not
unexpectedly, given the magnitude of the effect of er-
lotinib on these tumors, there was not any difference
in tumor regression mediated by erlotinib or erlotinib
plus the anti-PD-1 and/or CD40 agonist (Additional
file 1: Figure S7D&E). We then investigated whether
the CD40 agonist or anti-PD-1 treatment could in
combination with erlotinib delay tumor relapse. To
test this, we treated tumor-bearing mice, induced with
doxycycline for 6–7 weeks, with erlotinib alone or a
combination of erlotinib plus the CD40 agonist or
anti-PD-1 for 4 weeks (Fig. 7a), (n = 5–10 mice per
group). As expected after 4 weeks there was no de-
tectable tumor by MRI, with complete tumor shrink-
age in all treatment groups (Additional file 1: Figure
S7E). At the end of 4 weeks, the mice were taken off
erlotinib but continued on the CD40 agonist, anti-
PD-1 or the CD40 agonist plus anti-PD-1 (Fig. 7a).
We did not see any benefit on survival or tumor bur-
den quantified by MRI (Fig. 7b and Additional file 1:
Figure S7F).
Discussion
In this study, we investigated the changes that occur
within the immune microenvironment in a mouse model
of EGFR mutant lung cancer after treatment with the
TKI erlotinib. We found that erlotinib treatment led to
the re-establishment of most features of the immune
microenvironment found in the lungs of healthy non-
tumor bearing mice. Importantly, the erlotinib-mediated
changes were not due to a direct effect of the TKIs on
cells in the immune microenvironment but rather they
were stimulated by the process of tumor regression it-
self. However, despite increases in cytokine-producing
CD4 and CD8 T cells following erlotinib-treatment,
combination treatment with immunotherapies like anti-
PD-1 or a CD40 agonist did not effectively prevent
tumor relapse.
Given the increasing interest in combining targeted
therapies and immunotherapies, efforts to study the con-
sequences of targeted therapies on the tumor immune
microenvironment are growing [43]. Our findings dem-
onstrating that erlotinib-mediated tumor regression is
partially immunostimulatory are consistent with obser-
vations made with EGFR TKIs and with other targeted
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therapies. Studies of the BRAF inhibitor vemurafenib in
a mouse model of Braf mutant and Pten deficient melan-
oma showed increased cytokine producing T cells in tu-
mors following kinase inhibitor treatment [41, 44].
Similarly, activated CD8 cells were also more abundant
in a Kit mutant gastrointestinal stromal tumor (GIST)
model after imatinib treatment [45]. EGFR TKIs have
also been shown to have immunostimulatory properties
(that we now understand are likely due to the tumor re-
gression that they induce). Venugopalan and colleagues
demonstrated that 24 h after TKI treatment, when ex-
tensive cell death is occurring, immune cell infiltration
in the lungs of mouse models of EGFR mutant lung can-
cer is increased [25]. Jia and others also showed an in-
creased population of immune cells in this model after
TKI treatment, with the maximum effect observed 48 h
after treatment [46]. Prior to our study, the conse-
quences of TKIs like erlotinib on the immune micro-
environment after maximum tumor regression had not
been examined. Since TKIs are administered daily and
patients receive these therapies continuously, under-
standing the longer-term consequences of these drugs
on the immune microenvironment is critical. The im-
mune cell infiltration patterns found at 24 h [25] and 2
weeks (in our study) are similar consistent with the
possibility that the process of tumor regression serves as
a trigger for these changes. These indications of immune
activation were counterbalanced by data indicating that
after erlotinib treatment the tumors retained some im-
munosuppressive properties including abundant regula-
tory T cells (Fig. 1c) and increased levels of PD-L1 (Fig.
6d and e). While the Tregs may be indicative of immuno-
suppression persistent after erlotinib, the cells may also
be playing a role in tissue repair after inflammation [47].
Whether targeting these elements of immunosuppres-
sion would be an effective strategy to slow tumor growth
is currently unknown and actively being investigated.
Such studies could include direct targeting of Tregs either
by using antibodies such as ipilimumab (anti-CTLA-4)
that can deplete Tregs [48] or, in genetically engineered
mouse models, by ablating Tregs [49]. PD-1 axis inhibi-
tors have been shown to modestly prolong survival of
mice with EGFR mutant lung cancer [16], however,
whether in combination with erlotinib this translates
into improved survival and/or delays the emergence of
resistance is unknown. In patients, the response rate of
EGFR mutant tumors to PD-1 or PD-L1 blockade is
below 10% and therefore lower than in NSCLC as a
whole (RR ~ 20%) potentially due to the lower immuno-
genicity of the tumors mainly arising in former/never
A
B
Fig. 7 Boosting T cell function does not prevent recurrence after erlotinib treatment. (a) Experimental design and (b) survival curves of the
erlotinib and immunotherapy combination study. CCSP-rtTA; TetO-EGFRL858R mice were treated with erlotinib alone or in combination with
immunomodulatory agents as in arms 1–4 for 4 weeks after which erlotinib was halted and immunotherapy continued until mice were
moribund, (n = 5–10 mice per group)
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smokers and having a low mutational background [14,
50–52]. Large studies of TKIs in combination with
checkpoint inhibitors have not been conducted to date
in part due to concerns regarding the toxicity of these
combinations. However, in a small study of erlotinib in
combination with nivolumab, the combination was well-
tolerated and the response rate to the combination in
the refractory setting was 15% suggesting that some pa-
tients benefit from these agents [17]. We attempted to
determine whether leveraging the immune cell changes
in the TME mediated by erlotinib with an immunothera-
peutic agent like anti-PD-1 or an agonistic CD40 anti-
body could further stimulate the immune system to
exert anti-tumor effects. We found that addition of these
agents to erlotinib treatment did not prevent or delay
tumor relapse. These data indicate that the tumors are
refractory to T-cell mediated killing even when T cells
are abundant and not exhausted. It has been established
that lung tumors in genetically engineered mouse
models, including the EGFRL858R model we used, have a
significantly lower frequency of nonsynonymous muta-
tions compared to human lung adenocarcinomas [53,
54]. The low frequency of somatic mutations that arise
during tumor development in these models lead to the
generation of few neoantigens to induce T cell responses.
This may explain the lack of a strong T cell-mediated
immune response in this tumor model [55]. Future stud-
ies aimed to study antigen-specific T cell responses in
new systems that express model antigens and/or have
higher mutation burdens more reflective of human lung
cancer are ongoing. An alternative but not mutually ex-
clusive possibility is that multiple immunosuppressive
pathways active in the tumors need to be simultaneously
inhibited to engage the immune system. This is
supported by our data showing that Tregs represent a sig-
nificant fraction of T cells that are present in EGFRL858R-
induced tumors following erlotinib treatment. The ex-
tent to which these signals play a role in tumorigenesis
and need to be reversed for tumor regression is still
poorly understood.
There are several ways in which targeted therapies
may be affecting immune cells. They could either be act-
ing directly via on-target or off-target activities on im-
mune cells present in the tumor. Alternatively, the
changes could be an indirect consequence of the bio-
logical effects (e.g induction of apoptosis) of targeted
therapies. Indeed, forms of cell death, like necrosis, have
long been recognized as having potentially immunogenic
consequences, and data suggest that apoptosis could also
have immunological effects [56]. In support of this, our
study provides evidence that the TKI erlotinib itself does
not act directly on immune cells in the tumor micro-
environment but rather changes in immune infiltrates
result indirectly from the process of tumor regression.
First, we found that in a mouse model of erlotinib-
resistant lung cancer in which tumors do not regress
upon treatment with the TKI, low numbers and func-
tionally impaired CD4 and CD8 lymphocytes are found
similar to untreated tumors even following TKI treat-
ment. Second, erlotinib did not affect the proportion of
lymphocytes in the lungs of healthy non-tumor bearing
mice. Third, erlotinib treatment of lymphocytes isolated
from tumor-bearing mouse lungs or from spleen does
not affect their proliferation or activation. Others have
shown that erlotinib does inhibit the proliferation of T
cells isolated from mouse lymph nodes [23]. It is pos-
sible that these differences are due to the different bio-
logical contexts examined, namely lung or spleen cells
from tumor-bearing or LCMV-infected mice as opposed
to T cells from wild-type lymph nodes. Erlotinib has also
been shown to act directly on tumor cells by increasing
MHC I antigen presentation rendering them more re-
sponsive to T-cell mediated attack [57]. However, it is
unclear whether such mechanisms would be in play in
EGFR mutant tumor cells that are undergoing apoptosis
but rather in EGFR wild-type tumor cells where erlotinib
does not lead to cell death.
Our study has several translational implications. First,
the data underscore the difficulty of harnessing CD8 T
cell cytotoxicity in the context of poorly antigenic tu-
mors like those present in these mouse models of EGFR
mutant lung cancer. It is possible that strategies to lever-
age the immune system that do not rely on CD8 T cells
may be more successful in these tumors such as target-
ing innate immune cells. Indeed, depletion of alveolar
macrophages has been shown to reduce tumor burden
in these models [35] suggesting that targeting these cells
may be an avenue for therapeutic benefit. Second, our
study highlights how the process of tumor regression it-
self leads to the observed changes in the tumor immune
microenvironment rather than representing a direct ef-
fect of erlotinib on immune cells. Understanding the
contributions of individual drugs to the tumor immune
microenvironment can be important for selecting thera-
peutic combinations to maximize efficacy and minimize
toxicity. In the case of EGFR mutant lung cancer, where
there are concerns about combining TKIs with immuno-
therapies, like immune checkpoint inhibitors due to tox-
icity, it is possible that other agents that lead to tumor
regression could be used. This could be relevant in tu-
mors resistant to TKIs when TKI treatment is no longer
an option and other approaches need to be explored.
A limitation of our study is the absence of confirma-
tory evidence of our findings in TKI-responsive tumor
specimens from patients. Such samples are challenging
to obtain because biopsies are not routinely performed
when a tumor is responding to therapy. Future clinical
trials of TKIs that include on-treatment biopsies like the
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ELIOS Study (NCT03239340) will be valuable to evalu-
ate TKI-induced changes in the tumor microenviron-
ment in human tumors. An additional limitation of our
study is the low mutation burden of tumors in genetic-
ally engineered mouse models [53]. Even though our
model provides a physiologically relevant tumor micro-
environment, the low frequency of somatic mutations
that arise during tumor development limits the number
of neoantigens that can induce T cell responses.
Conclusions
Altogether, our findings lay the foundation for under-
standing how TKIs modulate the tumor immune micro-
environment and their association with the process of
tumor regression. These studies also provide us with
insight into the features of the immune tumor micro-
environment under continuous TKI exposure and
whether these can be leveraged therapeutically.
Additional file
Additional file 1: Figure S1. MRI images, histology and representative
flow cytometry plots of normal or tumor-bearing lungs before and after
erlotinib. (A) Coronal images of CCSPrtTA; TetO-EGFRL858R mouse lungs be-
fore (left panel) and after (right panel) treatment with erlotinib. (B)
Hematoxylin and eosin (H&E) stain of lungs from control (normal) and
tumor bearing CCSP-rtTA; TetO-EGFRL858R mice in the absence (−) and
presence (+) of erlotinib for 2 weeks. Bar: 50 μm. Absolute number of (C)
CD4 and (D) CD8 T cells normalized to weight of lungs of control (nor-
mal) and tumor bearing CCSP-rtTA; TetO-EGFRL858R mice in the absence
(−) and presence (+) of erlotinib for 2 weeks. Representative FACS plot
showing percentage of (E) FoxP3+ and FoxP3- CD4+ T cells (F) PD1+
FoxP3+ T cells. (G) Immunofluorescence (IF) stain of lung epithelial cells
(green), CD3 T cells (red) and FoxP3 Tregs (Cyan). Nuclei were counter-
stained with Dapi (blue) (H) Quantification of FoxP3+ CD3 T cells in lung
tumor bearing CCSP-rtTA; TetO-EGFRL858R mice in the absence (−) and
presence (+) of erlotinib for 2 weeks stained by IF. Data are shown as
mean ± SD and * is P < 0.05 in a student’s t-test. NS, non-significant.
Figure S2. Representative flow cytometry plots of cytokine producing T
cells and gene expression profile of T cells isolated from tumor-bearing
lungs before and after erlotinib. Representative FACS plots showing the
percentage of (A) TNF-α+, IFN-γ+, and IL-2+ CD4 T cells. (B) Quantifica-
tion of GzmB+ CD4 and CD8 T cells after PMA/ionomycin stimulation
and intracellular cytokine staining of cells in the lungs of tumor bearing
CCSP-rtTA; TetO-EGFRL858R mice in the absence (−) and presence (+) of
erlotinib for 2 weeks. (C) Representative FACS plot showing percentage of
GzmB+ splenic CD8 T cells after PMA/ionomycin stimulation and intracellular
cytokine staining of cells. (D) CD8 and (E) CD4 T cells isolated from CCSP-rtTA;
TetO-EGFRL858R tumor bearing mice untreated or treated with
erlotinib. Heatmap was generated using normalized expression values. NS,
non-significant. Figure S3. MRI images, histology and representative flow
cytometry plots of erlotinib sensitive and resistant tumors. (A) Coronal
images of: CCSP-rtTA; TetO-EGFRL858R mouse lungs before (left panel) and
after (right panel) cessation of doxycyline and CCSP-rtTA; TetO-EGFRL858R +
T790M mouse lungs before (left panel) and after (right panel) treatment with
2 erlotinib. (B) Hematoxylin and eosin (H&E) stain of lungs from tumor bear-
ing: CCSP-rtTA; TetO-EGFRL858R untreated or taken off doxycycline diet for 2
weeks and CCSP-rtTA; TetOEGFRL858R+ T70M mice in the absence (−) and pres-
ence (+) of erlotinib for 2 weeks. Bar: 50 μm. Absolute number of (C) CD4
and (D) CD8 T cells normalized to weight of lungs of tumor bearing CCSP-
rtTA; TetO-EGFRL858R or CCSP-rtTA; TetO-EGFRL858R + T790M mice in the absence
(−) and presence (+) of erlotinib for 2 weeks or taken off doxycycline diet.
Data are obtained from three independent experiments, (n = 4–6 mice per
group) * is P < 0.05 in a student’s t-test. Quantification of (E) CD4 and CD8 T
cells and (F) FoxP3 positive CD4 T cells in the lungs of control (normal) mice
in the absence (−) and presence (+) of erlotinib for 2 weeks. Data are shown
as the mean ± SD. NS, non significant. Figure S4. Quantification of circulat-
ing and proliferating T cells. (A) Absolute number and (B) Fold change in
number of circulating lung CD4 and CD8 T cells of tumor bearing CCSP-rtTA;
TetO-EGFRL858R mice in the absence (−) and presence (+) of erlotinib for 2
weeks. (C) Ki-67+ CD4 and CD8 T cells of tumor bearing CCSP-rtTA; TetO-
EGFRL858R mice in the absence (−) and presence (+) of erlotinib for 2 weeks
or mice taken off doxycycline for 2 weeks. Data are shown as the mean ±
SD and * is P < 0.05 in a student’s t-test. NS, non-significant. Figure S5. Ex-
perimental outline of CFSE labeling and analysis. (A) Flow chart for isolation,
labeling and treatment of T cells from lungs and spleens of tumor bearing
CCSP-rtTA; TetO-EGFRL858R mice. FACS plot showing (B) as a control for the
technique, unlabeled vs CFSE
labeled splenocytes (Day 0) and (C) Untreated CD4 and CD8 T cells from
lungs and spleens at Day 0 as well as CD4 and CD8 T cells from lungs and
spleens treated with 10 μm erlotinib or DMSO after 5 days (120 h).
Figure S6. Quantification of proliferating alveolar macrophages and
myeloid cells in healthy lungs before and after erlotinib treatment. (A) Ki-67
positive AMs, (B) Cxcl2 expression in AMs, (C) Cd274 mRNA expression in
Epcam+ tumor cells from lungs of control (normal) and tumor bearing
CCSP-rtTA; TetO-EGFRL858R mice in the absence (−) and presence (+) of erloti-
nib for 2 weeks. (D) Quantification of myeloid cell populations in the lungs
of control (normal) mice in the absence (−) and presence (+) of erlotinib for
2 weeks. Data are shown as the mean ± SD and * is P < 0.05 in a student’s t-
test. NS, non-significant. Figure S7. Tumor volume measurements and
survival analysis. Quantification of (A) CD8+ T cells, (B) Ki-67+ CD8+ T cells
and (C) Eomes+ CD8+ T cells in the lungs of tumor bearing CCSP-rtTA; TetO-
EGFRL858R mice in the absence (−) and presence (+) of erlotinib, CD40 agon-
ist or
erlotinib plus the CD40 agonist for 2 weeks, (n = 4–6 mice per group). (D)
Tumor volume quantified at 1 and 2 weeks after treatment measured by
MRI
normalized to pretreatment tumor volume. Change in tumor volume (E)
pre-treatment and 1–4 weeks after treatment with erlotinib alone or
erlotinib and immunotherapy combination and (F) pretreatment, 1–4 weeks
after treatment with erlotinib alone or erlotinib and immunotherapy
combination and 1–3 weeks after stopping erlotinib (relapse), (n = 5–10
mice per group). Data are shown as the mean ± SD and * is P < 0.05 in a
student’s t-test. NS, non-significant. (XLSX 66 kb)
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